Novel therapeutics in breast cancer-Looking to the future

Update on Cancer Therapeutics

Volumn 3, Issue 4, 2009, Pages 189-205

  Vora, Tushar ^a   de Azambuja, Evandro ^a   Awada, Ahmad ^a   Piccart, Martine ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Breast cancer; Epothilones; HER 2; HSP 90; IGF 1R; mTOR; PKC inhibitors and PARP1 inhibitors; Trastuzumab DM1

Indexed keywords

4 [3 CHLORO 4 (2 PYRIDINYLMETHOXY)ANILINO] 3 CYANO 6 (4 DIMETHYLAMINOCROTONAMIDO) 7 ETHOXYQUINOLINE; 9,10 DIDEHYDROEPOTHILONE D; ALVESPIMYCIN; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; BEVACIZUMAB; BIIB 021; CAPECITABINE; DJ 927; DOCETAXEL; EPOTHILONE B; EPOTHILONE DERIVATIVE; ERTUMAXOMAB; IXABEPILONE; JNJ 28871063; LAPATINIB; LAROTAXEL; NERATINIB; PACLITAXEL; PERTUZUMAB; PLACEBO; SAGOPILONE; TAMOXIFEN; TANESPIMYCIN; TAXANE DERIVATIVE; TRASTUZUMAB; TRASTUZUMAB DM1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ANEMIA; ANOREXIA; ARTHRALGIA; ASTHENIA; BRAIN METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER THERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; DEHYDRATION; DIARRHEA; DIZZINESS; ENZYME BLOOD LEVEL; FATIGUE; FEBRILE NEUTROPENIA; HEADACHE; HEART LEFT VENTRICLE EJECTION FRACTION; HEMORRHAGIC COLITIS; HUMAN; HYPOGLYCEMIA; HYPONATREMIA; INFLAMMATION; INJECTION SITE REACTION; KERATITIS; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; NAUSEA; NAUSEA AND VOMITING; NEPHRITIS; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PAIN; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; RECOMMENDED DRUG DOSE; RESPIRATORY DISTRESS SYNDROME; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; SYNCOPE; SYSTOLIC DYSFUNCTION; THROMBOCYTOPENIA; VOMITING;

EID: 67749103760     PISSN: 1872115X     EISSN: 1872115X     Source Type: Journal    
DOI: 10.1016/j.uct.2009.07.001     Document Type: Review

References (151)

1. Peppercorn J., Perou C.M., and Carey L.A. Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest 26 (2008) 1-10
2. Lin N.U., and Winer E.P. Advances in adjuvant endocrine therapy for postmenopausal women. J Clin Oncol 26 (2008) 798-805
3. Boughey J.C., Buzdar A.U., and Hunt K.K. Recent advances in the hormonal treatment of breast cancer. Curr Probl Surg 45 (2008) 13-55
4. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
5. Ferretti G., Felici A., Papaldo P., et al. HER2/neu role in breast cancer: from a prognostic foe to a predictive friend. Curr Opin Obstet Gynecol 19 (2007) 56-62
6. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001) 783-792
7. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 (2005) 1659-1672
8. Smith I., Procter M., Gelber R.D., et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369 (2007) 29-36
9. Cobleigh M.A., Vogel C.L., Tripathy D., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17 (1999) 2639-2648
10. Vogel C.L., Cobleigh M.A., Tripathy D., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20 (2002) 719-726
11. Bedard P.L., Cardoso F., and Piccart-Gebhart M.J. Stemming resistance to HER-2 targeted therapy. J Mammary Gland Biol Neoplasia 14 (2009) 55-66
12. Baselga J., Tripathy D., Mendelsohn J., et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14 (1996) 737-744
13. Agus D.B., Akita R.W., Fox W.D., et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2 (2002) 127-137
14. Jackson J.G., St Clair P., Sliwkowski M.X., et al. Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects. Cancer Res 64 (2004) 2601-2609
15. Franklin M.C., Carey K.D., Vajdos F.F., et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5 (2004) 317-328
16. Garrett T.P., McKern N.M., Lou M., et al. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell 110 (2002) 763-773
17. Kasprzyk P.G., Song S.U., Di Fiore P.P., et al. Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies. Cancer Res 52 (1992) 2771-2776
18. Spiridon C.I., Ghetie M.A., Uhr J., et al. Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. Clin Cancer Res 8 (2002) 1720-1730
19. Friedman L.M., Rinon A., Schechter B., et al. Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc Natl Acad Sci USA 102 (2005) 1915-1920
20. Portera C.C., Walshe J.M., Rosing D.R., et al. Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin Cancer Res 14 (2008) 2710-2716
21. NCI: CTC criteria version 3.0; 2008.
22. Gelmon KA, Fumoleau P, Verma S, et al. Results of a phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy; 2008. p. 1026.
23. NIH: a study to evaluate pertuzumab + trastuzumab + docetaxel vs. placebo + trastuzumab + docetaxel in previously untreated Her2-positive metastatic breast cancer (CLEOPATRA); 2009.
24. Zeidler R., Mysliwietz J., Csanady M., et al. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 83 (2000) 261-266
25. Zeidler R., Reisbach G., Wollenberg B., et al. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol 163 (1999) 1246-1252
26. Riesenberg R., Buchner A., Pohla H., et al. Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM × alpha CD3). J Histochem Cytochem 49 (2001) 911-917
27. Ruf P., and Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 98 (2001) 2526-2534
28. Kiewe P., Hasmuller S., Kahlert S., et al. Phase I trial of the trifunctional anti-HER2 × anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res 12 (2006) 3085-3091
29. NIH: ertumoxamab and phase II; 2009.
30. Jager M, Ruf P, Schoberth A, et al. Effect on low HER2 (1+) expressing tumor cells of the trifunctional antibody ertumaxomab; 2008. p. 3071 [ASCO abstracts].
31. Spector N.L., Xia W., Burris III H., et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 23 (2005) 2502-2512
32. Cameron D., Casey M., Press M., et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 112 (2008) 533-543
33. Tomasello G., de Azambuja E., Dinh P., et al. Jumping higher: is it still possible? The ALTTO trial challenge. Expert Rev Anticancer Ther 8 (2008) 1883-1890
34. Rabindran S.K., Discafani C.M., Rosfjord E.C., et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 64 (2004) 3958-3965
35. Wong K.K., Fracasso P.M., Bukowski R.M., et al. HKI-272, an irreversible pan erbB receptor tyrosine kinase inhibitor: preliminary phase 1 results in patients with solid tumors. J Clin Oncol 24 (2006) 3018
36. Burstein H, Awada A, Badwe R, et al. Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor: Preliminary Phase 2 Results in patients with advanced breast cancer. San Antonio Breast Cancer Symposium 2007 Poster 6061.
37. NIH: neratinib and breast cancer; 2009.
38. Stemmler H.J., Schmitt M., Willems A., et al. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 18 (2007) 23-28
39. Clayton A.J., Danson S., Jolly S., et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 91 (2004) 639-643
40. Emanuel S.L., Hughes T.V., Adams M., et al. Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors. Mol Pharmacol 73 (2008) 338-348
41. Modi S., Beeram M., Krop I.E., et al. A phase I study of trastuzumab-DM1 (T-DM1), a first-in-class HER2-antibody drug conjugate (ADC). In: Patients (pts) with HER2+ metastatic breast cancer (BC). ASCO breast cancer symposium 2007 poster 168 (2007)
42. Beeram M., Burris H.A., Modi S., et al. A phase I study of trastuzumab-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with advanced HER2+ breast cancer (BC). J Clin Oncol 26 (2008)
43. Lewis Phillips G.D., Li G., Dugger D.L., et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 68 (2008) 9280-9290
44. Krop I.E., Mita M., Burris H.A., et al. A phase I study of weekly dosing of trastuzumab-DM1 (T-DM1) in patients with advanced HER2+ breast cancer. San Antonio breast cancer symposium (2008) [abstract 3136]
45. Vukelja S., Rugo H., Vogel C., et al. A phase II study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+ metastatic breast cancer. San Antonio breast cancer symposium (2008) [abstract 33]
46. NIH: an open-label study of trastuzumab-MCC-DM1 (TDM-1) vs. capecitabine + lapatinib in patients with HER2-positive locally advanced or metastatic breast cancer; 2009.
47. ®) in patients with metastatic HER2-positive breast cancer who have not received prior chemotherapy for metastatic disease; 2009.
48. Meyer P., Prodromou C., Hu B., et al. Structural and functional analysis of the middle segment of hsp90: implications for ATP hydrolysis and client protein and cochaperone interactions. Mol Cell 11 (2003) 647-658
49. Pearl L.H., Prodromou C., and Workman P. The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J 410 (2008) 439-453
50. Banerji U. Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res 15 (2009) 9-14
51. Powers M.V., and Workman P. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer 13 Suppl. 1 (2006) S125-S135
52. Munster P.N., Basso A., Solit D., et al. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters. Clin Cancer Res 7 (2001) 2155-2158 2228-36
53. Schiff P.B., Fant J., and Horwitz S.B. Promotion of microtubule assembly in vitro by taxol. Nature 277 (1979) 665-667
54. Michaud L.B., Valero V., and Hortobagyi G. Risks and benefits of taxanes in breast and ovarian cancer. Drug Saf 23 (2000) 401-428
55. ten Tije A.J., Verweij J., Loos W.J., et al. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 42 (2003) 665-685
56. Rowinsky E.K., Eisenhauer E.A., Chaudhry V., et al. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20 (1993) 1-15
57. Windebank A.J., Blexrud M.D., and de Groen P.C. Potential neurotoxicity of the solvent vehicle for cyclosporine. J Pharmacol Exp Ther 268 (1994) 1051-1056
58. van Tellingen O., Huizing M.T., Panday V.R., et al. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br J Cancer 81 (1999) 330-335
59. Hennenfent K.L., and Govindan R. Novel formulations of taxanes: a review. Old wine in a new bottle?. Ann Oncol 17 (2006) 735-749
60. Liebmann J., Cook J.A., Lipschultz C., et al. The influence of Cremophor EL on the cell cycle effects of paclitaxel (Taxol) in human tumor cell lines. Cancer Chemother Pharmacol 33 (1994) 331-339
61. Ibrahim N.K., Desai N., Legha S., et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8 (2002) 1038-1044
62. Desai N., Trieu V., Yao Z., et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12 (2006) 1317-1324
63. Gradishar W.J., Tjulandin S., Davidson N., et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23 (2005) 7794-7803
64. Guan Z., Feng F., Li Q.L., et al. Randomized study comparing nab-paclitaxel with solvent-based paclitaxel in Chinese patients (pts) with metastatic breast cancer (MBC). J Clin Oncol 25 (2007)
65. Gradishar W, Krasnojon D, Cheporov S, et al. Randomized comparison of nab-paclitaxel weekly or every 3 weeks compared to docetaxel every 3 weeks as first-line therapy in patients (pts) with metastatic breast cancer (MBC). EBCC 2008 Poster 409.
66. NIH: bevacizumab and paclitaxel, paclitaxel albumin-stabilized nanoparticle formulation, or ixabepilone in treating patients with locally recurrent, stage iiib, or stage iv breast cancer; 2009.
67. Trieu V., Frankel T., Labao E., et al. SPARC expression in breast tumors may corelate to increased tumor distribution of nanoparticle albumin-bound paclitaxel (ABI-007) vs taxol. Proc Am Soc Cancer Res 46 (2005) 5548
68. Shionoya M., Jimbo T., Kitagawa M., et al. DJ-927, a novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo. Cancer Sci 94 (2003) 459-466
69. Baas P., Szczesna A., Albert I., et al. Phase I/II study of a 3 weekly oral taxane (DJ-927) in patients with recurrent, advanced non-small cell lung cancer. J Thorac Oncol 3 (2008) 745-750
70. Bissery M.C. Preclinical evaluation of new taxoids. Curr Pharm Des 7 (2001) 1251-1257
71. Dieras V., Limentani S., Romieu G., et al. Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy. Ann Oncol 19 (2008) 1255-1260
72. Heinz D.W., Schubert W.D., and Hofle G. Much anticipated-the bioactive conformation of epothilone and its binding to tubulin. Angew Chem Int Ed Engl 44 (2005) 1298-1301
73. Lee F.Y., Borzilleri R., Fairchild C.R., et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 7 (2001) 1429-1437
74. Lee F.Y., Camuso A., and Castaneda S. Preclinical studies of ixabepilone (BMS-247550) demonstrate optimal antitumor activity against both chemotherapy sensitive and resistant tumor types. Proc Am Assoc Cancer Res 47 (2006)
75. Lee F.Y., Camuso A., and Castenada C. Preclinical efficacy evaluation of ixabepilone in combination with cetuximab or capecitabine in human colon and lung carcinoma xenografts. J Clin Oncol 24 (2006) 12017
76. Lee F.Y., Castenada S., Inigo I., et al. Ixabepilone plus trastuzumab combination chemotherapy induces synergistic antitumor efficacy in Her2 dependent breast cancers and is accompanied by modulation of molecular response markers. J Clin Oncol 23 (2005) 561
77. Lee F., Castenada S., Hawkin D., et al. Bevacizumab/ixabepilone combination produces synergistic antitumor efficacy in multiple tumor models in vivo and is superior to bevacizumab/paclitaxel combination. AACR-NCI-EORTC International conference on molecular targets and cancer therapeutics. Philadelphia, PA (2005)
78. Thomas E.S., Gomez H.L., Li R.K., et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 25 (2007) 5210-5217
79. Gadgeel S.M., Wozniak A., Boinpally R.R., et al. Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design. Clin Cancer Res 11 (2005) 6233-6239
80. Hortobagyi G.N.E.P., Vrdoljak E., Medina C., et al. Analysis of overall survival (OS) among patients (pts) with metastatic breast cancer (MBC) receiving either ixabepilone (I) plus capecitabine (C) or C alone: results from two randomized phase III trials. ASCO abstract - 186 (2008)
81. Gradishar W.J., Wedam S.B., Jahanzeb M., et al. Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer. Ann Oncol 16 (2005) 1297-1304
82. Buzdar A.U., Hortobagyi G.N., Asmar L., et al. Prospective randomized trial of paclitaxel alone versus 5-fluorouracil/doxorubicin/cyclophosphamide as induction therapy in patients with operable breast cancer. Semin Oncol 24 (1997) S17-31-S17-34
83. Baselga J., Zambetti M., Llombart-Cussac A., et al. Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. J Clin Oncol 27 (2009) 526-534
84. Hoffmann J., Fichtner I., Lemm M., et al. Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases. Neuro Oncol 11 (2009) 158-166
85. NIH: combination chemotherapy followed by docetaxel or ixabepilone in treating patients who have undergone surgery for nonmetastatic breast cancer; 2009.
86. Abrey LE, Wen P, Govindan R, et al. Patupilone for the treatment of recurrent/progressive brain metastases in patients (pts) with non-small cell lung cancer (NSCLC): an open-label phase II study; 2008. p. 2033.
87. Conlin A.K., D'Andrea G., Hudis C.A., et al. Phase II trial of patupilone in patients (pts) with breast cancer brain metastases (BCBM) progressing or recurring after whole brain radiation therapy (WBXRT). ASCO annual meeting, vol. 26, No 15S (May 20 Supplement) (2008) 1086 [abstract 2008]
88. Hoffmann J., Fichtner I., Lemm M., et al. Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases. Neuro Oncol (2008)
89. Hoffmann J., Vitale I., Buchmann B., et al. Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone. Cancer Res 68 (2008) 5301-5308
90. NIH: safety and efficacy study of a new chemotherapy agent to treat metastatic breast cancer; 2009.
91. Stopeck A., Thomas E., Jones S., et al. Phase I trial of novel eopthilone, KOS-1584, using a weekly dosing schedule. ASCO annual meeting proceedings part I, vol. 24, No. 18S (June 20 supplement). J Clin Oncol (2006)
92. Stopeck A., Moulder S., Jones S., et al. Phase I trial of KOS-1584 (a novel epothilone) using two weekly dosing schedules. ASCO annual meeting proceedings part I. vol. 25, No. 18S (June 20 Supplement), 2007. J Clin Oncol (2007) 2571
93. Cardoso F., de Azambuja E., and Lago L.D. Current perspectives of epothilones in breast cancer. Eur J Cancer 44 (2008) 341-352
94. Kamath A.V., Chang M., Lee F.Y., et al. Preclinical pharmacokinetics and oral bioavailability of BMS-310705, a novel epothilone B analog. Cancer Chemother Pharmacol 56 (2005) 145-153
95. Sessa C., Perotti A., Llado A., et al. Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule. Ann Oncol 18 (2007) 1548-1553
96. Nielsen T.O., Andrews H.N., Cheang M., et al. Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17-allylamino geldanamycin. Cancer Res 64 (2004) 286-291
97. Sell C., Rubini M., Rubin R., et al. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci USA 90 (1993) 11217-11221
98. Rosenthal S.M., and Cheng Z.Q. Opposing early and late effects of insulin-like growth factor I on differentiation and the cell cycle regulatory retinoblastoma protein in skeletal myoblasts. Proc Natl Acad Sci USA 92 (1995) 10307-10311
99. Hamelers I.H., van Schaik R.F., Sipkema J., et al. Insulin-like growth factor I triggers nuclear accumulation of cyclin D1 in MCF-7S breast cancer cells. J Biol Chem 277 (2002) 47645-47652
100. Coats S., Flanagan W.M., Nourse J., et al. Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle. Science 272 (1996) 877-880
101. Harris L.N., You F., Schnitt S.J., et al. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 13 (2007) 1198-1207
102. Haluska P., Shaw H.M., Batzel G.N., et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 13 (2007) 5834-5840
103. Weroha S.J., and Haluska P. IGF-1 receptor inhibitors in clinical trials-early lessons. J Mammary Gland Biol Neoplasia 13 (2008) 471-483
104. Dunn S.E., Hardman R.A., Kari F.W., et al. Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Res 57 (1997) 2687-2693
105. Gooch J.L., Van Den Berg C.L., and Yee D. Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death-proliferative and anti-apoptotic effects. Breast Cancer Res Treat 56 (1999) 1-10
106. Campbell R.A., Bhat-Nakshatri P., Patel N.M., et al. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 276 (2001) 9817-9824
107. Cohen B.D., Baker D.A., Soderstrom C., et al. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 11 (2005) 2063-2073
108. Nahta R., Yuan L.X., Zhang B., et al. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 65 (2005) 11118-11128
109. Barbet N.C., Schneider U., Helliwell S.B., et al. TOR controls translation initiation and early G1 progression in yeast. Mol Biol Cell 7 (1996) 25-42
110. Chan S. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 91 (2004) 1420-1424
111. Fasolo A, Gianni L, Rorive A, et al. Multicenter phase I clinical trial of daily and weekly RAD001 (everolimus) in combination with vinorelbine and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer with prior resistance to trastuzumab. San Antonio Breast Cancer Symposium 2008. Poster 406.
112. Di Cosimo S., and Baselga J. Targeted therapies in breast cancer: where are we now?. Eur J Cancer 44 (2008) 2781-2790
113. Baselga J., van Dam P.A., Greil R., et al. Improved clinical and cell cycle response with an mTOR inhibitor, daily oral RAD001 (everolimus) plus letrozole versus placebo plus letrozole in a randomized phase II neoadjuvant trial in ER+ breast cancer. J Clin Oncol 26 May (Suppl.) (2008) [abstr 530]
114. Dowsett M., Smith I.E., Ebbs S.R., et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 99 (2007) 167-170
115. O'Brian C., Vogel V.G., Singletary S.E., et al. Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue. Cancer Res 49 (1989) 3215-3217
116. Lee S.A., Karaszkiewicz J.W., and Anderson W.B. Elevated level of nuclear protein kinase C in multidrug-resistant MCF-7 human breast carcinoma cells. Cancer Res 52 (1992) 3750-3759
117. Jasinski P., Terai K., Zwolak P., et al. Enzastaurin renders MCF-7 breast cancer cells sensitive to radiation through reversal of radiation-induced activation of protein kinase C. Eur J Cancer 44 (2008) 1315-1322
118. Soh J.W., Lee Y.S., and Weinstein I.B. Effects of regulatory domains of specific isoforms of protein kinase C on growth control and apoptosis in MCF-7 breast cancer cells. J Exp Ther Oncol 3 (2003) 115-126
119. Kiley S.C., Clark K.J., Duddy S.K., et al. Increased protein kinase C delta in mammary tumor cells: relationship to transformtion and metastatic progression. Oncogene 18 (1999) 6748-6757
120. Sledge Jr. G.W., and Gokmen-Polar Y. Protein kinase C-beta as a therapeutic target in breast cancer. Semin Oncol 33 (2006) S15-S18
121. Graff J.R., McNulty A.M., Hanna K.R., et al. The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 65 (2005) 7462-7469
122. Rademaker-Lakhai J.M., Beerepoot L.V., Mehra N., et al. Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer. Clin Cancer Res 13 (2007) 4474-4481
123. Camidge D.R., Gail Eckhardt S., Gore L., et al. A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors. Anticancer Drugs 19 (2008) 77-84
124. Mina L, Krop I, Zon RT, et al. A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane containing regimen. Invest New Drugs DOI: 10.1007/s10637-009-9220-1.
125. NIH: enzastaurin plus fulvestrant vs. placebo plus fulvestrant in breast cancer; 2009.
126. NIH: enzastaurin in combination of capecitabine to treat breast cancer.
127. NIH: trial of paclitaxel, bevacizumab, and enzastaurin versus paclitaxel, bevacizumab and placebo for breast cancer; 2009.
128. Graziani G., and Szabo C. Clinical perspectives of PARP inhibitors. Pharmacol Res 52 (2005) 109-118
129. Farmer H., McCabe N., Lord C.J., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434 (2005) 917-921
130. Rottenberg S., Jaspers J.E., Kersbergen A., et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 105 (2008) 17079-17084
131. O'Shaughnessy J, Yoffe M, Osborne C, et al. Triple negative breast cancer: a phase 2, multi-center, open-label, randomized trial of gemcitabine/carboplatin (G/C), with or without BSI-201, a PARP inhibitor. San Antonio Breast Cancer Symposium 2008. Poster 2120.
132. NIH: Phase I/II AZD2281/cisplatin in neoadjuvant treatment of triple negative breast cancer patients; 2009.
133. NIH: neoadjuvant studies of Lapatinib; 2009.
134. Modi S., Stopeck A.T., Gordon M.S., et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 25 (2007) 5410-5417
135. Modi S., Sugarman S., Stopeck A., et al. Phase II trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC). J Clin Oncol 26 May (Suppl.) (2008) [abstr 1027]
136. Modi S, Miller K, Rosen LS, et al. Alvespimycin (KOS-1022) and trastuzumab (T): Activity in HER2+ metastatic breast cancer (MBC). ASCO Breast cancer symposium 2007. Abstract 165.
137. Flaherty K.T., Gore L., Avadhani A.N., et al. First use of an oral Hsp90 inhibitor in patients (Pts) with solid tumors: Alvespimycin (A) administered QOD or QD. J Clin Oncol 26 May (Suppl.) (2008) [abstr 2502]
138. Elfiky A., Saif M.W., Beeram M., et al. BIIB021, an oral, synthetic non-ansamycin Hsp90 inhibitor: Phase I experience. J Clin Oncol 26 May (Suppl.) (2008) [abstr 2503]
139. NIH: CP-751871 in treating women with early-stage breast cancer that can be removed by surgery; 2009.
140. NIH: IMC-A12 and temsirolimus in treating patients with locally recurrent or metastatic breast cancer; 2009.
141. NIH: a study for safety and effectiveness of imca12 by itself or combined with antiestrogens to treat metastatic breast cancer in patients who progressed on antiestrogen therapy; 2009.
142. NIH: capecitabine and lapatinib with or without monoclonal antibody therapy in treating patients with previously treated HER2-positive stage IIIb, stage IIIc, or stage IV breast cancer; 2009.
143. NIH: Amgen protocol no. 20060362-a study of AMG 479 with exemestane or fulvestrant in postmenopausal women with hormone receptor positive locally advanced or metastatic breast cancer; 2009.
144. NIH: a study to establish proof-of-biology for MK0646 in breast cancer; 2009.
145. ®) in subjects with advanced or metastatic Her-2-positive breast cancer; 2009.
146. Carpenter J.T.H.R., Campone M., Colomer R., et al. Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer. 2005 ASCO annual meeting proceedings. vol. 23, no. 16S, Part I of II (June 1 Suppl.). J Clin Oncol (2005) 564.
147. Chow L.W.C., Sun Y., Jassem J., et al. Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. San Antonio breast cancer symposium (2006) [abstract 6091]
148. Hahn OM, Ma CX, Lin L, et al. A phase II trial of a mammalian target of rapamycin inhibitor, temsirolimus, in patients with metastatic breast cancer. San Antonio Breast Cancer Symposium. 2008. Abstract 407.
149. Awada A., Cardoso F., Fontaine C., et al. The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. Eur J Cancer 44 (2008) 84-91
150. Fasolo A, Gianni L, Rorive A, et al. Multicenter phase I clinical trial of daily and weekly RAD001 (everolimus) in combination with vinorelbine and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer with prior resistance to trastuzumab. San Antonio Breast Cancer Symposium 2008. Poster 406.
151. O'Regan R, Andre F, Campone M, et al. RAD001 (everolimus) in combination with weekly paclitaxel and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer with prior resistance to trastuzumab: a multicenter phase I clinical trial. San Antonio Breast Cancer Symposium. 2008 Abstract 3119.